A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors
一项针对晚期实体肿瘤患者持续口服 OSI-906(胰岛素样生长因子 1 和胰岛素受体的双重抑制剂)的 I 期研究
期刊:Clinical Cancer Research
影响因子:10
doi:10.1158/1078-0432.CCR-14-0303
Igor Puzanov, Colin R Lindsay, Laura Goff, Jeff Sosman, Jill Gilbert, Jordan Berlin, Srinivasu Poondru, Ronit Simantov, Rich Gedrich, Andrew Stephens, Emily Chan, T R Jeffry Evans